AU · rank #1 · 2026-09-07
PGEN
NASDAQ · $2.46B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.513 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.48 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $24,662 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $14.50 | +104.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +75.66% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.75 |
| Gross margin TTM | +53.0% |
| 52w high | $7.72 |
| Market cap (USD) | $2.46B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Precigen is a commercial-stage gene therapy company whose entire revenue base rests on PAPZIMEOS, the first-and-only FDA-approved therapy for recurrent respiratory papillomatosis, which achieved its first quarterly net profit in Q2 2026 on ~$53M in product sales.
Rationale
The 104% analyst upside, 100% revision agreement, a 475% earnings surprise, and sequential revenue doubling all reinforce the analyst_upside strategy's logic that consensus has been structurally too bearish and is now catching up to a genuine commercial inflection.
Material risks
- 1Single-product concentration in a niche orphan indication means any reimbursement disruption, safety signal, or payer pushback on PAPZIMEOS pricing would collapse the entire revenue thesis with no pipeline backstop.
- 2Coverage by only 3 analysts with high target dispersion (48%) and zero net upgrades in 90 days suggests the upside signal is driven by target raises rather than broad institutional conviction, making the stock vulnerable to a sentiment reversal if Q3 growth decelerates from the Q2 surge.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.